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Motor neurons are cells located in specific areas of the central nervous system, such as brain cortex (upper motor
neurons), brain stem, and spinal cord (lower motor neurons), which maintain control over voluntary actions. Motor
neurons are affected primarily by a wide spectrum of neurological disorders, generally indicated as motor neuron
diseases (MNDs): these disorders share symptoms related to muscular atrophy and paralysis leading to death. No
effective treatments are currently available. Stem cell-derived motor neurons represent a promising research tool in
disease modeling, drug screening, and development of therapeutic approaches for MNDs and spinal cord injuries.
Directed differentiation of human pluripotent stem cells - human embryonic stem cells (hESCs) and human induced
pluripotent stem cells (hiPSCs) - toward specific lineages is the first crucial step in order to extensively employ these
cells in early human development investigation and potential clinical applications. Induced pluripotent stem cells
(iPSCs) can be generated from patients’ own somatic cells (for example, fibroblasts) by reprogramming them with
specific factors. They can be considered embryonic stem cell-like cells, which express stem cell markers and have
the ability to give rise to all three germ layers, bypassing the ethical concerns. Thus, hiPSCs constitute an appealing
alternative source of motor neurons. These motor neurons might be a great research tool, creating a model for
investigating the cellular and molecular interactions underlying early human brain development and pathologies
during neurodegeneration. Patient-specific iPSCs may also provide the premises for autologous cell replacement
therapies without related risks of immune rejection. Here, we review the most recent reported methods by which hESCs
or iPSCs can be differentiated toward functional motor neurons with an overview on the potential clinical applications.Introduction
Motor neurons (MNs) are differentiated cells that con-
trol voluntary actions and are affected primarily by a
wide spectrum of neurological disorders, generally indi-
cated as motor neuron diseases (MNDs). MNDs may
present with a range of symptoms deriving from muscu-
lar weakness/atrophy and leading to death [1]. Currently,
no effective treatment exists for these illnesses.
Every year, MNDs affect approximately 2 new cases
per 100,000 people, and the prevalence of these disor-
ders is about 5 to 7 cases per 100,000 [2]. MNDs are* Correspondence: stcorti@yahoo.it
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2014usually more common in men than women, and the
incidence rate is 2:1 [3]. The life expectancy of patients
with MND is quite variable: for about half of these disor-
ders, death occurs 3 to 5 years from the onset of symp-
toms, but some people may live for more than 10 years,
whereas in other cases the disease can be very rapidly
progressive. Reasons accounting for such variability
remain poorly understood.
MNDs can be classified in relation to the subpopula-
tion of MNs affected mainly by the disease process as
spinal muscular atrophy (SMA), progressive muscular
atrophy, spinobulbar muscular atrophy (or Kennedy’s
disease), and hereditary motor neuropathies involving
lower MNs. Among them, SMA is the most common
disease during childhood [4]. SMA is an autosomal
recessive disease: the majority of patients with SMAl Ltd. The licensee has exclusive rights to distribute this article, in any medium,
this time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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neuron 1), resulting in the selective degeneration of
lower α-MNs. The SMN2 gene, an SMN1 homologue,
compensates for the abnormal production of SMN1 pro-
tein, and its levels of expression correlate with disease
severity [5]. The pathology involves spinal cord MNs
causing their degeneration and ultimately death.
Upper MNs are more vulnerable in primary lateral
sclerosis, hereditary spastic paraplegias, and spinal mus-
cular atrophy with respiratory distress type 1 [6].
Finally, disease processes that affect both upper and
lower MN populations, such as amyotrophic lateral
sclerosis (ALS), can be reported. ALS is mostly sporadic
(SALS), and familial forms of ALS (FALS) account for
10% of cases [7]. C9orf72 expansion has been observed
in the majority of FALS cases [8], but many other genes
have been involved in ALS etiopathogenesis such as
Tar-DNA-binding protein 43 (TDP-43), fused in sarcoma
protein (FUS) [9], and superoxide dismutase (SOD1) [10].
ALS incidence is 1 to 2 per 100,000 persons every year,
and the age of onset is around 50 to 60 years: symptoms
develop from paralysis to death within 2 to 5 years from
the diagnosis [7].
Pathological mechanisms underlying the onset of ALS
and generally MNDs are largely unknown. Many factors
seem to be involved in the process with different contri-
butions from environmental and genetic factors [11].
Stem cell-derived MNs represent a promising research
tool in disease modeling, drug screening, and develop-
ment of therapeutic approaches for MNDs and spinal
cord injuries [12,13]. They could provide a replacement
for dying cells and a trophic support within the central
nervous system (CNS) [12].
In regard to the latter, stem cells may be supportive for
endogenous cells modulating the diseased microenviron-
ment by providing neurotrophic factors and scavenging
toxic catabolites.
Particularly in the case of neurodegeneration, the poten-
tial positive effects due to cell replacement are related to
the complexity of the pre-built host system. To effectively
replace lost cells, transplanted ones should integrate
within the host circuits and establish proper connections
eventually reaching long-distance targets through the in-
hibitory white matter. So far, several transplantation strat-
egies have focused on the more achievable ‘paracrine’
effect [14], in which transplanted cells act therapeutically
through the secretion of diffusible factors. Several studies
report a therapeutic effect of stem cells due to the trophic
modulation of the neurodegenerated environment in
different models of neurological disorders (that is,
Parkinson’s disease, stroke, and Huntington’s disease)
[15]. Proceeding beyond this strategy, stem cells can
also be engineered to secrete selected molecules at the
disease site [16]; human neural progenitor cells (hNPCs)modified by using lentivirus to secrete glial cell-derived
neurotrophic factor (GDNF) integrated properly within
ALS animal models. After transplantation into the
spinal cord of SOD1 (G93A) rats, a significant cell mi-
gration toward disease sites was observed together with
efficient delivery of GDNF. A considerable preservation
of MNs at early and end stages of the disease was shown
within chimeric regions [17]. Similarly, hNPCs have
been modified to release GDNF upon stimulation; cells
have been transplanted in the striatum of a rodent
model and could survive and effectively express GDNF,
paving the way to further studies in Parkinson’s disease
animal models [18].
Recent years have brought several advances in the stem
cell field, concerning methods of both reprogramming
and differentiation. Stem cells can be defined by their abil-
ity to replicate indefinitely while maintaining the capacity
to form cells of the three germinal layers (ectoderm, endo-
derm, and mesoderm lineages). The several categories of
stem cells reflect the wide range of cell types derivable
and the ways in which stem cells are obtained.
Human embryonic stem cells (hESCs) are derived
from the inner cell mass of the blastocyst, they are pluri-
potent, and they can be maintained in vitro for a good
period of time with a stable genetic background, provid-
ing a source of specialized human cells for biological
and clinical applications [19,20]. Directed differentiation
of hESCs toward specific lineages is the first crucial step
in order to extensively employ hESCs in early human de-
velopment investigation as well as in potential future
clinical applications. However, their use can raise ethical
issues, and the therapeutic applications could imply risks
of negative reaction, such as immune reactions or devel-
opment of tumors or both [21].
Induced pluripotent stem cells (iPSCs) can be derived
from patients’ somatic cells by reprogramming them
with specific factors [22]. They can be considered em-
bryonic stem cell (ESC)-like cells, which express stem
cell markers and have the ability to give rise to all three
germ layers, bypassing the ethical concerns. Specific in-
dividual human-derived iPSCs provide the premises for
cell replacement therapy without the related risks of im-
mune rejection. Thus, human induced pluripotent stem
cells (hiPSCs) constitute an appealing alternative source
for MN differentiation. Different methods have been
reported for iPSC derivation. Viral methods (generally
the most efficient ones) present major risks related to
the stochastic activation/inactivation of endogenous
genes. Non-integrative methods (that is, proteins, RNAs,
mRNAs, and plasmids carrying the reprogramming
factors) have been developed to bypass this concern and
facilitate the transition to clinical practice [23].
During the last decades, increasing efforts have been
made to direct specific differentiation of stem cells
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ported that ESCs and iPSCs are responsive in vitro to
the same developmental stimuli guiding neural specifica-
tion in vivo and are able to give rise to differentiated
neuronal cells with specific morphological and molecular
signatures. Obtaining fully differentiated cells is crucial
to model in simplified in vitro platforms the complex
processes underlying physiological development and
disease pathogenetic mechanisms, with the ultimate aim
to find a cure for orphan disorders.
This could be particularly important for those patholo-
gies, such as MNDs, for which obtaining affected rele-
vant cells from human patients can be challenging.
Indeed, some of the first reported examples about gener-
ating human disease-specific cells are related to MNDs
[24,25]. Many issues need to be addressed to effectively
translate iPSCs to large-scale preclinical studies; among
them is the assessment of standardized efficient proto-
cols of differentiation and of homogenous parameters to
evaluate the obtained cell phenotype. In the case of
spinal MNs, efforts aiming to point out rapid and highly
efficient differentiation methods are being pursued
worldwide.
In the present review, we will first describe the funda-
mental steps regulating MN specification in vivo; data
obtained from these studies have guided the assessment
of experimental differentiation protocols in vitro. We
will focus our attention on MN differentiation derivedDorsal
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Figure 1 Schematic representation of the role of morphogens during
expression levels of each morphogen. Bone morphogen protein (BMP) can
(light green): its levels decrease along the ventral part. In contrast, Sonic he
is not expressed in the dorsal one. Fibroblast growth factor (FGF) is highly
the neural tube. Retinoic acid (RA) levels of expression decrease in the pos
can be found. MN, motor neuron.from hESCs and iPSCs; the most used methods of neural
induction will be reviewed. Neural induction is the first
crucial step to obtain neural progenitors through neural
rosette and embryoid body (EB) formation. Then, neural
progenitors can be differentiated with different protocols
varying for rapidity and efficiency. We will give an
overview of the most recent published methodologies
together with the different methods of evaluation of
obtained MNs. Finally, we will consider potential clinical
applications of hiPSC/ESC-derived MNs with a focus on
MND modeling and treatment, paying attention to the
biological challenges that we need to address before trans-
lating promising preclinical data into clinical application.
Motor neuron development
During embryogenesis, patterning and cell fate specifica-
tion are regulated by the local production and secretion
of protein morphogens and growth factors. Neurogen-
esis is the developmental process by which the whole
nervous system is generated; it starts from the ectoder-
mal plaque that folds over on itself, giving rise to the
neural tube. The neural tube grows along rostrocaudal
and dorsoventral axes, and during this process the cellu-
lar differentiation is induced by morphogenetic factors
and signaling molecules secreted by neighboring cells
(Figure 1) [26]. Morphogens induce the activation of
intracellular pathways that, through the activation of
specific transcriptional factors, cause a specific geneticPosterior
FGF
RA
FGF 
Wnt
MNs
neural tube formation in vivo. Color gradients are indicative of the
be found in high concentrations in the dorsal part of the neural tube
dgehog (Shh) is more concentrated in the ventral part (orange), but it
expressed in the anterior (purple) and posterior (dark green) parts of
terior part (light blue), where high concentrations of both FGF and Wnt
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particular, specification of spinal MN fate is determined
by three steps: neuralization, caudalization, and ventrali-
zation [27].
The term neuralization refers to the specification of
the ectodermal cells toward epidermis or neural fate.
This specification is influenced by the bone morphogen
protein (BMP) that belongs to the transforming growth
factor-beta (TGF-β) superfamily of proteins [28]. There-
fore, neural induction is initiated through inhibition of
both BMP and TGF-β/SMAD signaling [29]. Spinal
MNs are diversified along the rostrocaudal axis by retin-
oic acid (RA) [30], which induces neuralization and cau-
dalization and Wnt and fibroblast growth factor (FGF)
signals [31] that promote an anterior or rostral pattern
[32]. Ventral patterning is controlled by Sonic hedgehog
(Shh) that directs ventralization of the spinal neural pro-
genitor cell [33], whereas dorsal patterning is controlled
by members of the BMP family [34].
BMP factors are selectively located in the ‘roof plate’
regions of the dorsal neural tube. Other growth factors
are expressed specifically by the most ventral region
(‘floor plate’). The roof plate gives rise to the interneu-
rons, whereas the region of floor plate is the site of ori-
gin of developing MNs. The dorsoventral axis of the
neural tube is established by Wnt morphogenetic signal-
ing gradients: high concentration of Wnt determinates
the dorsal region, whereas Shh signaling defines the ven-
tral region [35]. Wnt proteins are also involved in axon
guidance within the spinal cord in an anterior-posterior
direction [36].
Understanding pathways and specific morphogens that
regulate MN development is crucial to replicate in vitro
some of these physiological steps in order to obtain
enriched MN populations starting from human iPSCs
and ESCs. At present, there are many protocols that
exploit morphogens or synthetic agonists to promote
MN specification [37,38].
Motor neuron generation from human pluripotent
stem cells
Different methods for MN differentiation have been
performed (Table 1); here, we summarize a selection of
the recently published and most significant protocols
for obtaining a highly pure population of MNs differen-
tiated from human pluripotent stem cells (hESCs and
hiPSCs).
Neural induction
The term neural induction refers to the formation of
neural progenitors deriving from pluripotent stem cells.
There are several methods to promote neural induction;
the majority include neural rosette and EB formation
(Figure 2).Neural rosettes can be considered a stage at which
neural stem cells exhibit a high proliferative potential and
broad differentiation capacity along both neuronal and
glial lineages in response to appropriate developmental
signals [48]. Neural rosettes are defined by their specific
cytoarchitecture, gene expression, and extrinsic growth re-
quirements. To generate neural rosettes, hESCs and iPSCs
are usually seeded on poly-L-lysine/laminin-coated culture
dishes and maintained under adhesion conditions. Cells
are usually plated in neurobasal medium supplemented
with N2 and B27 for the growth and long-term viability of
post-mitotic neurons. The medium can be additionally
supplemented with mouse/human recombinant Noggin
[37,46] or Dorsomorphin, which are employed as inhibitors
of BMP signaling to enhance neural induction [29,38,46].
Alternatively, stem cells can be cultured on stromal feeder
[49] or transferred in modified TeSR1 medium until cells
adhere and rosette structures appear [50].
Reinhardt and colleagues [29] reported the generation
of hNPCs using only small molecules. These neural pro-
genitors do not require manual selection and they are also
able to differentiate into neural tube lineages, including
MNs. The authors also hypothesized that Wnt, in combin-
ation with Shh, might contribute to the maintenance of
neural precursors. Neural induction was promoted through
inhibition of both BMP and TGF-β signaling using Dorso-
morphin and SB43152. To stimulate the canonical Wnt
signaling, CHIR99021, a GSK3β inhibitor, was added to the
cell medium and the Shh pathway was stimulated by using
purmorphamine.
In recent years, many groups have exploited protocols
focused on the formation of EBs to differentiate stem cells
into MNs. EBs are three-dimensional cell aggregates that
grow spontaneously, self-assembling in suspension cul-
tures. For EB formation, iPSCs or ESCs are detached from
mouse embryonic feeder fibroblasts and cultivated onto
ultralow adherent culture dishes. Cell culture medium is
similar to the one used for hESC culture, supplemented
with TGF-β and BMP inhibitors. Media usually contain
Noggin or a small-molecule substitute, like Y-27632 [51] to
increase cell survival, SB435142 and LDN193189 to pro-
mote neural induction [39], and FGF to enhance growth.
Some authors adopted a combination of the two methods:
EBs were cultivated in a suspension environment and then
the aggregates were dissociated and seeded on laminin/
poliornithin-coated plates to form neural rosettes [25,43].
Motor neuron generation
Thanks to the cultural background of developmental biol-
ogy, it is known that MN differentiation in vitro appears
to summarize the sequence of events physiologically
involved in spinal cord development. In 2002, Wichterle
and colleagues [27] were the first ones to exploit RA and
Shh to differentiate mouse ESCs through EB formation;
Table 1 Experimental protocols for motor neuron induction from human embryonic and induced pluripotent stem cells
References Starting
cells
Neural induction MN differentiation MN maturation Duration
Medium Factors Obtained cells Medium Factors Medium Factors
Amoroso et al.
[39]
ESCs and
iPSCs
ESC mediuma Y27632, bFGF,
LDN193189, and
SB435142
Embryoid bodies Neural induction
mediumb
RA, ascorbic acid,
BDNF, C25II modified
Shh, SAG, HAG, or
purmorphamine
Neurobasal medium IGF1, GDNF,
CNTF, and B27
20-30
days
Boulting et al.
[40]
ESCs and
iPSCs
ESC medium with
10% KO replacement
bFGF and
Y27632
Embryoid bodies Neural induction
mediumb
supplemented
with bFGF
RA, ascorbic acid,
db-cAMP, and HAG
Neurobasal medium BDNF, GDNF,
and CNTF
29 days
Burkhardt et al.
[41]
iPSCs DMEM/F12 supplemented
with N2, B27, and NEAA
Y27632,
Dorsomorphin
dihydrochloride
Embryoid bodies DMEM/F12,
GLUTAMAX,
N2, B27 serum-free
supplement,
D-Glucose,
and ascorbic acid
SAG, RA, and DAPT
(only for 4 days)
DMEM/F12,
GLUTAMAX
CNTF, BDNF,
and GDNF
32 days
N2, B27 serum
free supplement,
D-Glucose, and
ascorbic acid
Corti et al. [25] iPSCs DMEM/F12, NEAA, N2,
and heparin
RA Neural rosette DMEM/F12, NEAA,
N2, and heparin
RA and Shh DMEM/F12, NEAA,
N2, and heparin
BDNF, GDNF,
and IGF1
~24 days
Hester et al.
[42]
ESCs and
iPSCs
DMEM/F12, N2, and
10% KO serum
- Embryoid
bodies then
neural rosette
DMEM/F12 with
N2
RA, Shh, forskolin,
B27, and adenovirus
- - ~40 days
Hu and Zhang
[43]
ESCs DMEM/F12, KO serum
replacement, NEAA,
L-Glu, and BME
- Floating embryoid
bodies
Neural
differentiation
medium
(DMEM/F12,
N2, NEAA, and
heparin)
Shh or purmorphamine,
RA, B27, cAMP, ascorbic
acid, BDNF, GDNF,
and IGF1
Neural differentiation
medium (DMEM/F12,
N2, NEAA, and
heparin)
cAMP, ascorbic
acid, BDNF,
GDNF, and IGF1
~40 days
Karumbayaram
et al. [44]
iPSCs and
ESCs
ESC medium without
FGF2
- Embryoid bodies/
neural rosette
ESC medium
without FGF2
RA and
purmorphamine
DMEM/F12 and N2 GDNF, BDNF,
CNTF, Shh,
and RA
35-49
days
Reinhardt et al.
[29]
iPSCs and
ESCs
ESC mediuma and then
expansion medium
(DMEM/F12, N2, B27,
pen/strep, and L-Glu)
For induction:
SB435142,
Dorsomorphine,
CHIR, and
purmorphamine
Embryoid bodies
(smNPC)
Expansion
medium
(DMEM/F12,
N2, B27,
pen/strep,
and L-Glu)
Purmorphamine
and RA
Expansion N2, B27 BDNF, GDNF,
db-cAMP, RA,
and purmorphamine
>40 days
For expansion:
ascorbic acid,
CHIR99021, and
purmorphamine
Sareen et al.
[45]
iPSCs Neural differentiation
medium (DMEM, B27,
vitamin A, and N2)
RA Embryoid bodies Neurobasal
medium,
B27, and N2
RA and
purmorphamine
DMEM/F12 and B27 RA, purmorphamine,
db-cAMP, ascorbic
acid, BDNF, and GDNF
>40 days
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Table 1 Experimental protocols for motor neuron induction from human embryonic and induced pluripotent stem cells (Continued)
Takazawa et al.
[37]
ESCs ESC mediuma and then
DMEM/F12, N2, NEAA,
L-Glu, and heparin
Y27632, bFGF,
and recombinant
mouse Noggin
Embryoid bodies Wnt3a-L-cell
conditioned
medium
RA, ascorbic acid,
db-cAMP, and
recombinant mouse
Shh (C25II)
Neurobasal medium
with N2, B27, Glu,
and NEAA
Ascorbic acid,
db-cAMP, RA, Shh,
BDNF, GDNF, and IGF1
>31 days
Wada et al.
[46]
ESCs ESC mediuma
and FGF2
Noggin and
dorsomorphin
Neural rosette DMEM/F12, N2B27 Shh or SAG, RA DMEM/F12, N2, B27,
FGF2, and heparin
GDNF, BDNF, and NT3 38 days
FGF2, and EGF
Wichterle et al.
[27]
mESCs DFK5 medium
(DMEM/F12,
L-Glu, pen/strep,
BME, and insulin-
transferrin- selenium
supplement
RA, Shh,
Hedgehog
agonist
(Hh-Ag1.3),
or hedgehog
antibody (5E1)
Embryoid bodies DMEM/F12
medium
- DMEM/F12 GDNF, BDNF, CNTF,
and NT3
~25 days
Zeng et al.
[47]
iPSC (ESCs
as positive
control)
hESC mediuma N2 and heparin Neural rosette Neural mediumb RA, Shh, and FGF8 Neural basal medium,
N2, and B27
GDNF, BDNF, and IGF1 >24 days
aHuman embryonic stem cell (hESC) medium: Dulbecco’s modified Eagle’s medium (DMEM/F12), 20% knockout (KO) serum replacement, basal medium Eagle (BME), L-Glu, and non-essential amino acid (NEAA).
bNeural induction medium: L-Glu, NEAA, penicillin/streptomycin (pen/strep), heparin, and N2. BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth factor; CNTF, ciliary neurotrophic factor; EGF,
epidermal growth factor; ESC, embryonic stem cell; FGF, fibroblast growth factor; GDNF, glial cell-derived neurotrophic factor; HAG, human-specific Smo agonist; IGF1, insulin-like growth factor-1; iPSC, induced
pluripotent stem cell; mESC, murine embryonic stem cell; MN, motor neuron; RA, retinoic acid; SAG, Smo agonist; Shh, Sonic hedgehog; smNPC, small-molecule neural precursor cell.
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Figure 2 Generation of human motor neurons from human embryonic and induced pluripotent stem cells. A schematic representation
for motor neuron (MN) generation in vitro is shown. The first step in pluripotent stem cell - human embryonic stem cell (hESC) and human
induced pluripotent stem cell (hiPSC) - differentiation is the attainment of embryoid bodies (EBs) in suspension or neural rosettes in adhesion
conditions. These neural precursors can be successfully differentiated in MNs (characterized by specific features) with different multistage
experimental protocols. hESC- or iPSC-derived MNs are a promising research tool to model and study in vitro pathological mechanisms underlying
MN diseases in humans. These MNs could also represent an appealing source for autologous cell replacement. RA, retinoic acid; Shh,
Sonic hedgehog.
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adapted to promote MN commitment of hESCs as well.
Wada and colleagues [46] differentiated hESCs toward
MNs through neural rosette formation: neural precursors
derived from hESCs were treated with 1 μM RA and
500 ng/mL Shh, resulting in large numbers of Tubulin β
III+, Hb9+, Islet1+, and choline acetyltransferase-positive
(ChAT+) neurons. Transcriptional upregulation of MN
markers such as Islet 1, Hb9, and Olig2 was shown. Ter-
minally differentiated neurons were Synapsin-positive and
electrophysiologically active. MNs were capable of recreat-
ing neuromuscular junctions in culture with C2C12 myo-
tubule cells. Overall, these data indicate that hESCs can
differentiate into MNs that express specific molecularmarkers and have functional properties similar to those of
physiologically developed MNs. Through the years, many
reported protocols have tested different efficacious con-
centrations of the crucial signaling molecules, from 1 nM
to 1 μM of RA and from 50 to 500 ng/mL of Shh
[25,39,40,45].
Another crucial variable to be modulated is the time
of addition of the small molecules for differentiation. Hu
and Zhang [43] reported a protocol starting from hESCs
that were differentiated into MNs: cells were cultured
for 4 days in hESC medium and in neural differentiation
medium thereafter. In the second week, aggregates at-
tached to the surface of culture dishes and possessing
features of neuroepithelial rosettes could be isolated by
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neuroepithelial cells Olig2-positive at day 10 were much
more responsive to RA; thus, RA was added at day 10 in
their protocol. These Olig2-expressing cells then differ-
entiated to spinal motoneurons in the fifth week and
expressed transcription factors such as Hb9 and Islet1.
They reported that the optimized protocol typically gen-
erates over 50% of Hb9-expressing motoneurons from
the original hESC progenies.
Another variable to be considered is the natural habit
of human stem cells to differentiate into caudal/rostral
subtypes giving rise to medial/lateral column as well as
cranial MNs. Similarly, the selective differentiation signal
inducing the development of specific neuronal subtypes
within the wide range of spinal cord MNs warrants fur-
ther studies to be extensively applied in in vitro studies
and cell therapies. The manipulation of Hox gene net-
work specifying columnar and pool MN identity may be
fundamental to selectively modulate the differentiation
of precursor cells into specific MN subtypes. Recently,
Amoroso and colleagues [39] systematically compared
the ventralizing activity of three Smoothened agonists
using a standard RA/Shh protocol involving all-trans RA
and a modified Sonic hedgehog (Shh-C25II) protein as a
benchmark for differentiation of hESCs into MNs. To
evaluate MN numbers, they relied on the HUES3 Hb9:
GFP reporter line which contains a transgene expressing
green fluorescent protein (GFP) under the control of the
MN-specific Hb9 promoter. HUES3 cells were electro-
porated with a plasmid carrying a neomycin resistance
cassette and the GFP coding sequence upon transcrip-
tional control of Hb9 promoter restriction fragment. In
this way, stem cells were engineered in order to express
GFP under the control of the MN-specific reporter Hb9.
This strategy allows the study of cell morphology and
differentiation in culture and their tracing in vivo. How-
ever, it has to be considered that this marker does not
provide any information on motor neuronal subtype and
the fluorescence of GFP could give false-positive results
due to the GFP long half-life. Very few GFP+ cells were
observed in the absence of exogenous Shh agonists. Re-
combinant Shh and human-specific Smo agonist each
gave rise to less than 10% GFP+ cells. In contrast, the
Smo agonist (SAG) alone gave rise to 16% ± 4% GFP+
cells and purmorphamine alone induced 22% ± 6%.
RNA-seq analyses revealed an enrichment of spinal MN
markers and the expression of cholinergic genes in cells
treated with SAG and purmorphamine compared with
only Shh-treated ones. This work exploited non-viral
protocols of differentiation, characterized also by rela-
tively high rapidity and efficiency. Not less important,
Amoroso and colleagues [39] made great efforts in
selecting and validating a pool of specific markers to
evaluate the cell phenotype: Hb9 and ISL1 were foundto be alternatively expressed in approximately half of the
cells, not always co-expressed as originally believed.
Moreover, this differentiation method starting from
hESCs resulted in the generation of MNs expressing
FOXP1 (68% ± 4%), which is a marker of limb muscle-
innervating lateral motor column neurons. This regional
sub-specification could be important for disease model-
ing studies.
Many other differentiation cocktails have been re-
ported to share the objective of gaining highly enriched
spinal cord motor neuronal populations: supplementing
RA and Shh with B27 [43,46], cAMP [37,40,45], heparin,
brain-derived neurotrophic factor (BDNF), and ascorbic
acid [37,40,45]. López-González and colleagues [52] ana-
lyzed the effect of progesterone and 17β-estradiol on
MN differentiation of HBG3 ESCs. Progesterone treat-
ment during MN differentiation at EB stage, combined
with RA and Shh, induced higher proportions of MN
compared with RA/Shh alone [52].
The discovery and establishment of the use of iPSCs
provided further advances in the field; it has become
possible, by using hiPSCs, to produce MNs carrying the
specific combination of genetic variants that caused neu-
rodegeneration in a single patient. A multistage MN dif-
ferentiation protocol starting from SMA patient-derived
iPSCs has been performed by Corti and colleagues [25].
For MN generation, iPSCs derived from patients with
SMA were grown in a neuronal medium supplemented
with N2 and heparin. After 10 days, RA (0.1 μM) was
added for caudalization, and at day 17 the clusters of
posteriorized neuroectodermal cells were resuspended
for a week in the same medium with RA (0.1 μM) and
Shh (100 to 200 ng/mL). On day 24, BDNF, GDNF, and
insulin-like growth factor-1 were added for MN matur-
ation. Derived human MNs were characterized by the
expression of specific markers and carried the patho-
logical hallmarks of SMA disease.
This study provided important data on the potential
applications of stem cells both as in vitro models of dis-
ease and as a feasible therapeutic approach. In regard to
the former, generated MNs presented features indicative
of mature lineage and spinal MN commitment such as
HB9/ISLET1 and SMI32. The in vitro differentiation
protocol generated a mixed cell population, including
non-motor neuronal cells. To further isolate and purify
MNs, a physical strategy based on gradient centrifuga-
tion and leading to an enriched MN population was
exploited [25]. Moreover, SMA-iPSC-derived MNs
showed shorter axonal length, smaller growth cones, and
impaired ability to form neuromuscular junctions com-
pared with wild-type cells, hallmarks of MN disease. In
regard to the latter, reprogrammed cells have been ob-
tained with non-viral non-integrating methods, which
could be suitable for human therapy uses in the future.
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mouse model, there were no major signs of rejection but
rather a proper engraftment was documented with even
a partial rescue of the diseased phenotype.
Similarly, different methods have been performed for
MN induction starting from hiPSCs derived from pa-
tients affected by ALS. Sareen and colleagues [45] gener-
ated iPSC-derived MNs from patients with ALS by
growing iPSCs for 6 days in suspension with neural dif-
ferentiation medium enriched with RA for EB formation.
At day 17, cells were treated with neural induction
medium supplemented with RA and purmorphamine for
8 days. Then EBs were dissociated and single cells were
plated in medium with B27, RA, purmorphamine, db-
cAMP, ascorbic acid, BDNF, and GDNF for 2 to 7 weeks.
Derived MNs recapitulate the features of ALS disease
and can be employed to investigate cellular degeneration
processes and test new therapeutic compounds.
Derived motor neuron evaluation
The increasing expertise in differentiating MNs with dif-
ferent experimental protocol variables emphasizes the
necessity for continuous evaluation of derived MNs. To
exploit human stem cell-derived MNs in regenerative
medicine or in MND in vitro modeling, it is first neces-
sary to evaluate their proper differentiation, assessing
that they have the same features as MNs in vivo. An effi-
cient MN differentiation starting from human ESC and
iPSC lines can be assessed by evaluation of those fea-
tures that are the hallmarks of MNs in vivo (that is,
marker expression, morphology, and functional proper-
ties) (Figure 2). The authors demonstrated that hESC-
and hiPSC-derived MNs are characterized by the expres-
sion of the same specific markers previously assessed in
human MNs in vivo [25-27]. Indeed, the expression of
MN post-mitotic markers such as Hb9, HoxC8, ChAT,
and SMI-32 was evaluated by immunocytochemistry
assays, as was the expression of MN progenitor markers
like Pax6, Nestin, Olig2, and Islet1/2 and pan-neural
markers such as β-tubulin and anti-microtubule-
associated protein 2 [25,29,39,42,45].
Karumbayaram and colleagues [44] demonstrated that
MNs derived through neural rosette and EB formation
expressed MN progenitor markers (that is, Olig2 and
Nkx6.1) and also showed an enrichment of mature
markers like β-tubulin, ChAT, and Islet1. To further
characterize the expression of these markers in an un-
biased manner, authors usually perform Western blot,
PCR - quantitative reverse transcription-PCR and re-
verse transcription-PCR - and whole-transcriptome se-
quencing or RNA-seq to detect an enrichment of spinal
MN markers (Islet1, Islet2, and Hb9) and of CHAT,
CHT1, VACHT, CHRNA3, CHRNA4, and CHRNB2,
which are indicative of cholinergic identity [27,39].In several studies, stem cells were manipulated in
order to express GFP driven by an MN-specific reporter.
A reporter specific for activity of Hb9 which encodes for
a transcription factor specifically expressed by mature
MNs is most commonly used because of its relatively
high specificity and assessed staining.
Hb9-driven GFP reporter is usually transfected into
stem cells, allowing the identification of MNs in which
Hb9 is transcriptionally active. This technique facilitates
cell study in culture and cell tracing in vivo. Hb9:GFP
stem cells can be studied for their maturation in cellular
morphology (that is, branching and neurite outgrowth)
and increased soma area over time [29,39,44]. Other au-
thors developed Olig2:GFP lines in which an enhanced
GFP cassette was inserted to the Olig2 locus of hESCs
to target MN progenitors [53]. Electrophysiological ana-
lysis, including calcium imaging and whole-cell patch
clamp, showed that stem cell-derived MNs become elec-
trically active with prolonged time in culture and are re-
sponsive to glutamate agonist [27,34,38,39,49]. Takazawa
and colleagues [37] observed electrophysiological changes
associated with maturation of MNs differentiated from
stem cells, which included decreasing input resistance and
increasing action potential firing frequency. Furthermore,
these cells showed two peculiar characteristics of spinal
MNs in vivo: spike frequency adaptation and rebound
action potential firing [37].
In vivo morphological analyses can consist of xenotrans-
plants by injection of stem cell-derived MNs (usually Hb9:
GFP+ to be easily traced) into animal models. Pluripotent
stem cell-derived MNs demonstrated the ability to project
axons outside of the CNS through the ventral (and some-
times dorsal) roots and to follow proper neural paths
when transplanted into spinal cord of developing chickens
[39] or mice [25,29]. Furthermore, Corti and colleagues
[25] demonstrated that engrafted GFP-MNs co-expressed
pan-neuronal-specific markers and ChAT, formed new
neuromuscular junctions with skeletal muscles, and, once
transplanted into SMA model mice, induced an improve-
ment of neuromuscular phenotype and survival.
Clinical perspectives
Disease modeling
Disease modeling represents an interesting possibility of
application of human stem cell-derived MNs: with the
optimization of standardized protocols for stem cell differ-
entiation, it has become achievable to produce human
MNs in substantial amounts for elucidating in vitro basic
disease processes. Stem cells could also be manipulated in
order to express mutant genes related to MNDs [54,55].
The discovery of reprogramming methods using
specific factors and the subsequent derivation of the first
patient-specific hiPSC lines provided a further step in
this direction.
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and thus address specific questions about altered neur-
onal differentiation and function that might cause the
development of diseases such as ALS, SMA, and many
others. The possibility to recreate in vitro a reliable
model of human disease is valuable, as there have been
many examples of therapeutic approaches that were
relatively efficacious in animal models but unfortunately
did not translate well to patients [7].
Burkhardt and colleagues [41] reprogrammed fibroblasts
to iPSCs derived from a large cohort of healthy controls
and ALS patients and differentiated them into MNs. The
authors reported that MNs derived from three patients
with SALS possessed de novo TDP-43 aggregation and
that these aggregates summarized pathological features in
post-mortem tissue from one of the three patients from
which iPSCs were derived. The authors then performed a
high-content chemical screen by using the TDP-43 aggre-
gate endpoint in both lower MNs and upper derived MNs
identifying US Food and Drug Administration-approved
small-molecule modulators.
Corti and colleagues [25] generated iPSCs from SMA
patients with non-viral methods resulting in cells free
from vectors and transgenic sequences. SMA-iPSCs
were then differentiated into MNs with a multistage
differentiation protocol involving RA and Shh. MNs gen-
erated from SMA-iPSCs carried specific disease-related
features suggestive of selective MN degeneration such as
a reduction in MN survival and size as well as in axonal
growth and neuromuscular junction formation. Oligo-
deoxynucleotides to SMN2 were generated with a stable
genetic modification of a single nucleotide in exon 7,
leading to the modification of SMN2 coding region. As a
consequence, exon 7 was rescued, resulting in a greater
production of full-length SMN2. Phenotypes of MNs de-
rived from corrected and untreated SMA-iPSCs were
compared: gene correction with oligonucleotides rescued
neuropathological features in SMA MNs and correlated
with SMN expression. Transcriptional differences in the
SMA-iPSC MNs in comparison with treated SMA-iPSC
MNs were evaluated, revealing alterations in a subset of
genes involved in RNA metabolism, MN development,
and axonal guidance.
Thus far, various iPSC lines from patients with various
neurodegenerative disorders, including Alzheimer’s dis-
ease, Parkinson’s disease, and Huntington’s disease, have
been generated [56-58]. Patient-derived stem cells could
be one of the best complementary approaches to the use
of reliable animal models to identify and test therapeutic
compounds for neurological disorders.
Therapeutic transplants of human motor neurons
Cell therapy in neurodegenerative disorders acts by
introducing functional cells in order to rescue thefunction of damaged neural tissues. Transplantation of
hESC-derived MNs into the developing chick embryo re-
sulted in correct engraftment, maintenance of moto-
neuron identity and long-distance axon elongation
outside the CNS, reaching properly peripheral muscular
targets [49]. Transplantation into the adult rat spinal
cord resulted in neural engraftment, including a great
number of human MNs with sprout of ChAT+ fibers.
These data suggest that hESC-derived MNs may be able
to project toward the ventral root through the adult
spinal cord, similarly to the embryonic chick spinal cord
even if with a different time scale. This study provided
evidence for in vivo survival of hESC-derived MNs, a
crucial requirement for future preclinical applications.
hiPSCs are similar to hESCs, and the experimental
strategies developed for hESCs could be applied to iPSCs
without major modifications. In addition, hiPSCs do not
have issues in the immunologic compatibility between
donors and recipients reported in hESCs [57]. Thus,
they have been investigated as a promising source of au-
tologous cells for transplant therapy in neurological dis-
orders. iPSCs from patients with SMA (SMA-iPSCs)
were generated by using non-viral, non-integrating epi-
somal vectors: SMN2 gene was converted into an
SMN1-like gene with a strategy based on the use of
single-stranded oligonucleotides [25]. In vivo experi-
ments after transplantation into the spinal cord of trans-
genic SMA mice showed that iPSC-derived MNs can
survive and integrate into the spinal cord of SMA mice
and ameliorate the SMA type I phenotype. Transplanted
SMA mice had a longer survival (about 50%) compared
with vehicle-treated mice, a beneficial effect that was
more relevant with treated SMA-iPSC MNs than with
untreated ones [25].
These appealing premises for clinical therapies have to
be modulated by the presence of crucial issues to be ad-
dressed before effectively translating cell-mediated ap-
proaches to the clinic. Important concerns are related to
the generation and preparation of cells under good manu-
facturing practice (GMP). It has been demonstrated that
ESCs can be generated without the use of reagents of ani-
mal origin (xenobiotics); however, the derivation of
patient-specific iPSCs usually requires methods of repro-
gramming that are not performed in xeno-free conditions.
iPSCs generated with viral methods present major
risks related to the stochastic activation/inactivation of
endogenous genes. Non-integrative methods (that is, pro-
teins, RNAs, mRNAs, and plasmids carrying the repro-
gramming factors) have been improved to bypass this
concern and facilitate the transition to the clinic [23].
Neural stem cells to be transplanted can be obtained also
by direct reprogramming (induced neural stem cells, or
iNSCs): experimental protocols present fewer passages in
comparison with the generation of iPSCs, thus lessening
Faravelli et al. Stem Cell Research & Therapy Page 11 of 132014, 5:87
http://stemcellres.com/content/5/4/87the necessity of different quality-check points [59]. On the
other hand, iNSCs are a rather new source of stem cells
and consequently generation methods still need to be
standardized together with a precise evaluation of the ob-
tained phenotype [59]. In general, protocols of differenti-
ation toward a specific lineage, including rigorous
methods of data homogenization and standardization in
order to be reproducible, should be implemented. Several
xeno-free media preparations are commercially available,
together with GMP feeders [23]. Differentiated phenotype
needs to be rigorously evaluated, and different assessment
methods are usually combined to limit eventual unspecific
staining. Indeed, GMP optimized techniques to trace and
evaluate the state of transplanted cells will be necessary
after clinical translation. Finally, obtained cells should
undergo standardized quality control to assess viability,
sterility, and proper cell conformation (that is, karyotype
analysis, specific marker evaluation, and absence of xeno-
biotic contamination) [23].
Concerns related to the host immunorejection could
be bypassed with the use of autologous cells, such as
iPSCs. However, studies rigorously assessing iPSC im-
munogenicity still need to be performed, and results
could vary on the basis of cell preparation protocols.
The clinical perspectives on the use of cell-based ther-
apies have to be calibrated on the basis of the previous
issues: the premises for future treatments are great but
need to be thoroughly tested by standardized in vitro
studies at first and then by a rigorously assessed clinical
trial in humans.
Despite many aspects to be cleared and certainly
worthy of further studies (that is, ability of transplanted
MNs to survive, integrate, and project their axons for
long-distance innervating properly peripheral targets),
these preliminary results open the way to a future in
which human pluripotent stem cells may provide a
source of healthy MNs for therapeutic transplantation
for SMA and other MNDs.
Conclusions
The potential of human pluripotent stem cells to treat
patients with neurodegenerative disease is enormous.
Stem cells can be introduced into clinical applications in
several different ways, such as disease modeling, drug
screening, and cell replacement therapy.
The development and optimization of non-viral
methods of stem cell reprogramming will allow clini-
cians to bypass concerns related to random viral integra-
tion. The use of autologous patient cells could also
alleviate problems associated with host immunorejec-
tion. In regard to the production of differentiated cells,
it is crucial to assess protocols with high efficiency
allowing a large-scale production for quality-control as-
sessment. A very recently published study reported thegeneration of MNs from iPSCs in 20 days [60]. In view of
future clinical applications, it is necessary to integrate effi-
ciency and rapidity of production with constant attention
to working under GMP conditions, exploiting xeno-free
media, and conducting a careful quality-control assess-
ment. Recent progress in stem cell research has opened
new perspectives for in vitro generation of large numbers
of various neural cell types and for their use in the repair
of the nervous system. Advances in obtaining and under-
standing MNs have been made in recent years; however,
some aspects still need to be investigated. Among them,
the molecular signature of MN development and specifi-
cation into different subtypes in vivo is only partially
known. In regard to different methods exploited to
produce MNs, extensive applications need a precise
consideration of the experimental conditions for cell plat-
ing and culturing. Moreover, challenges such as those
ensuring clinical safety should be overcome. Even though
it may take quite a long time to address all of these ques-
tions, the establishment and optimization of human stem
cell differentiation protocols to develop hiPSC-based
clinical applications may hold the key to curing neurode-
generative disorders.
Abbreviations
ALS: Amyotrophic lateral sclerosis; BDNF: Brain-derived neurotrophic factor;
BMP: Bone morphogen protein; ChAT: Choline acetyltransferase; CNS: Central
nervous system; EB: Embryoid body; ESC: Embryonic stem cell; FALS: Familial
amyotrophic lateral sclerosis; FGF: Fibroblast growth factor; GDNF: Glial
cell-derived neurotrophic factor; GFP: Green fluorescent protein; GMP: Good
manufacturing practice; hESC: Human embryonic stem cell; hiPSC: Human
induced pluripotent stem cell; hNPC: Human neural progenitor cell;
iNSC: Induced neural stem cell; iPSC: Induced pluripotent stem cell;
MN: Motor neuron; MND: Motor neuron disease; PCR: Polymerase chain
reaction; RA: Retinoic acid; SAG: Smo agonist; SALS: Sporadic amyotrophic
lateral sclerosis; Shh: Sonic hedgehog; SMA: Spinal muscular atrophy;
SMN: Survival motor neuron; SOD1: Superoxide dismutase; TDP-43:
Tar-DNA-binding protein 43; TGF-β: Transforming growth factor-beta.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors read and approved the final manuscript.
Acknowledgments
We thank the Associazione Amici del Centro Dino Ferrari for their support.
Published:
References
1. Mitne-Neto M, Machado-Costa M, Marchetto MC, Bengtson MH, Joazeiro
CA, Tsuda H, Bellen HJ, Silva HC, Oliveira AS, Lazar M, Muotri AR, Zatz M:
Downregulation of VAPB expression in motor neurons derived from
induced pluripotent stem cells of ALS8 patients. Hum Mol Genet 2011,
20:3642–3652.
2. McDermott CJ, Shaw PJ: Diagnosis and management of motor neurone
disease. BMJ 2008, 336:658–662.
3. Orrell RW: GPs have key role in managing motor neurone disease.
Practitioner 2011, 255:19–22.
4. D’Amico A, Mercuri E, Tiziano FD, Bertini E: Spinal muscular atrophy.
Orphanet J Rare Dis 2011, 6:71.
14 Jul 2014
Faravelli et al. Stem Cell Research & Therapy Page 12 of 132014, 5:87
http://stemcellres.com/content/5/4/875. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou
B, Cruaud C, Millasseau P, Zeviani M, Le Paslier D, Frézal J, Cohen D,
Weissenbach J, Munnich A, Melki J: Identification and characterization of a
spinal muscular atrophy-determining gene. Cell 1995, 80:155–165.
6. Sau D, Rusmini P, Crippa V, Onesto E, Bolzoni E, Ratti A, Poletti A:
Dysregulation of axonal transport and motorneuron diseases. Biol Cell
2011, 103:87–107.
7. Gordon PH: Amyotrophic lateral sclerosis: an update for 2013 clinical features,
pathophysiology, management and therapeutic trials. Aging Dis 2013, 4:295–310.
8. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M,
Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N,
Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola
G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller
BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R: Expanded
GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes
chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245–256.
9. Lattante S, Rouleau GA, Kabashi E: TARDBP and FUS mutations associated
with amyotrophic lateral sclerosis: summary and update. Hum Mutat
2013, 34:812–826.
10. Rotunno MS, Bosco DA: An emerging role for misfolded wild-type SOD1
in sporadic ALS pathogenesis. Front Cell Neurosci 2013, 7:253.
11. Limpert AS, Mattmann ME, Cosford ND: Recent progress in the discovery
of small molecules for the treatment of amyotrophic lateral sclerosis
(ALS). Beilstein J Org Chem 2013, 9:717–732.
12. Lunn JS, Sakowski SA, Federici T, Glass JD, Boulis NM, Feldman EL: Stem cell
technology for the study and treatment of motor neuron diseases. Regen
Med 2011, 6:201–213.
13. Amemori T, Romanyuk N, Jendelova P, Herynek V, Turnovcova K, Prochazka
P, Kapcalova M, Cocks G, Price J, Sykova E: Human conditionally
immortalized neural stem cells improve locomotor function after spinal
cord injury in the rat. Stem Cell Res Ther 2013, 4:68.
14. Rossi F, Cattaneo E: Opinion: neural stem cell therapy for neurological
diseases: dreams and reality. Nat Rev Neurosci 2002, 3:401–409.
15. Rosser AE, Zietlow R, Dunnett SB: Stem cell transplantation for
neurodegenerative diseases. Curr Opin Neurol 2007, 20:688–692.
16. Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M,
Aebischer P, Svendsen CN: GDNF delivery using human neural progenitor
cells in a rat model of ALS. Hum Gene Ther 2005, 16:509–521.
17. Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, Aebischer P, Svendsen CN:
GDNF secreting human neural progenitor cells protect dying motor
neurons, but not their projection to muscle, in a rat model of familial
ALS. PLoS One 2007, 2:e689.
18. Behrstock S, Ebert A, McHugh J, Vosberg S, Moore J, Schneider B, Capowski
E, Hei D, Kordower J, Aebischer P, Svendsen CN: Human neural
progenitors deliver glial cell line-derived neurotrophic factor to
parkinsonian rodents and aged primates. Gene Ther 2006, 13:379–388.
19. Alvarez CV, Garcia-Lavandeira M, Garcia-Rendueles ME, Diaz-Rodriguez E,
Garcia-Rendueles AR, Perez-Romero S, Vila TV, Rodrigues JS, Lear PV, Bravo
SB: Defining stem cell types: understanding the therapeutic potential of
ESCs, ASCs, and iPS cells. J Mol Endocrinol 2012, 49:R89–R111.
20. Tsukamoto A, Uchida N, Capela A, Gorba T, Huhn S: Clinical translation of
human neural stem cells. Stem Cell Res Ther 2013, 4:102.
21. Jang J, Yoo JE, Lee JA, Lee DR, Kim JY, Huh YJ, Kim DS, Park CY, Hwang DY,
Kim HS, Kang HC, Kim DW: Disease-specific induced pluripotent stem
cells: a platform for human disease modeling and drug discovery.
Exp Mol Med 2012, 44:202–213.
22. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell 2006,
126:663–676.
23. Karumbayaram S, Lee P, Azghadi SF, Cooper AR, Patterson M, Kohn DB, Pyle
A, Clark A, Byrne J, Zack JA, Plath K, Lowry WE: From skin biopsy to
neurons through a pluripotent intermediate under Good Manufacturing
Practice protocols. Stem Cells Transl Med 2012, 1:36–43.
24. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W,
Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K:
Induced pluripotent stem cells generated from patients with ALS can be
differentiated into motor neurons. Science 2008, 321:1218–1221.
25. Corti S, Nizzardo M, Simone C, Falcone M, Nardini M, Ronchi D, Donadoni C,
Salani S, Riboldi G, Magri F, Menozzi G, Bonaglia C, Rizzo F, Bresolin N, Comi
GP: Genetic correction of human induced pluripotent stem cells from
patients with spinal muscular atrophy. Sci Transl Med 2012, 4:165ra162.26. Jessell TM: Neuronal specification in the spinal cord: inductive signals
and transcriptional codes. Nat Rev Genet 2000, 1:20–29.
27. Wichterle H, Lieberam I, Porter JA, Jessell TM: Directed differentiation of
embryonic stem cells into motor neurons. Cell 2002, 110:385–397.
28. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A: Bone
morphogenetic proteins: a critical review. Cell Signal 2011, 23:609–620.
29. Reinhardt P, Glatza M, Hemmer K, Tsytsyura Y, Thiel CS, Höing S, Moritz S,
Parga JA, Wagner L, Bruder JM, Wu G, Schmid B, Röpke A, Klingauf J,
Schwamborn JC, Gasser T, Schöler HR, Sterneckert J: Derivation and
expansion using only small molecules of human neural progenitors for
neurodegenerative disease modeling. PLoS One 2013, 8:e59252.
30. Muhr J, Graziano E, Wilson S, Jessell TM, Edlund T: Convergent inductive
signals specify midbrain, hindbrain, and spinal cord identity in gastrula
stage chick embryos. Neuron 1999, 23:689–702.
31. Storey KG, Goriely A, Sargent CM, Brown JM, Burns HD, Abud HM, Heath JK:
Early posterior neural tissue is induced by FGF in the chick embryo.
Development 1998, 125:473–484.
32. Liu JP, Laufer E, Jessell TM: Assigning the positional identity of spinal
motor neurons: rostrocaudal patterning of Hox-c expression by FGFs,
Gdf11, and retinoids. Neuron 2001, 32:997–1012.
33. Echelard Y, Epstein DJ, St-Jacques B, Shen L, Mohler J, McMahon JA,
McMahon AP: Sonic hedgehog, a member of a family of putative
signaling molecules, is implicated in the regulation of CNS polarity.
Cell 1993, 75:1417–1430.
34. Liem KF Jr, Tremml G, Roelink H, Jessell TM: Dorsal differentiation of neural
plate cells induced by BMP-mediated signals from epidermal ectoderm.
Cell 1995, 82:969–979.
35. Ulloa F, Marti E: Wnt won the war: antagonistic role of Wnt over Shh
controls dorso-ventral patterning of the vertebrate neural tube. Dev Dyn
2010, 239:69–76.
36. Zou Y: Wnt signaling in axon guidance. Trends Neurosci 2004, 27:528–532.
37. Takazawa T, Croft GF, Amoroso MW, Studer L, Wichterle H, Macdermott AB:
Maturation of spinal motor neurons derived from human embryonic
stem cells. PLoS One 2012, 7:e40154.
38. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer
L: Highly efficient neural conversion of human ES and iPS cells by dual
inhibition of SMAD signaling. Nat Biotechnol 2009, 27:275–280.
39. Amoroso MW, Croft GF, Williams DJ, O’Keeffe S, Carrasco MA, Davis AR,
Roybon L, Oakley DH, Maniatis T, Henderson CE, Wichterle H: Accelerated
high-yield generation of limb-innervating motor neurons from human
stem cells. J Neurosci 2013, 33:574–586.
40. Boulting GL, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ,
Williams DJ, Kahler DJ, Yamaki M, Davidow L, Rodolfa CT, Dimos JT,
Mikkilineni S, MacDermott AB, Woolf CJ, Henderson CE, Wichterle H, Eggan
K: A functionally characterized test set of human induced pluripotent
stem cells. Nat Biotechnol 2011, 29:279–286.
41. Burkhardt MF, Martinez FJ, Wright S, Ramos C, Volfson D, Mason M, Garnes
J, Dang V, Lievers J, Shoukat-Mumtaz U, Martinez R, Gai H, Blake R, Vaisberg
E, Grskovic M, Johnson C, Irion S, Bright J, Cooper B, Nguyen L, Griswold-
Prenner I, Javaherian A: A cellular model for sporadic ALS using
patient-derived induced pluripotent stem cells. Mol Cell Neurosci 2013,
56:355–364.
42. Hester ME, Murtha MJ, Song S, Rao M, Miranda CJ, Meyer K, Tian J, Boulting
G, Schaffer DV, Zhu MX, Pfaff SL, Gage FH, Kaspar BK: Rapid and efficient
generation of functional motor neurons from human pluripotent stem
cells using gene delivered transcription factor codes. Mol Ther 2011,
19:1905–1912.
43. Hu BY, Zhang SC: Differentiation of spinal motor neurons from
pluripotent human stem cells. Nat Protoc 2009, 4:1295–1304.
44. Karumbayaram S, Novitch BG, Patterson M, Umbach JA, Richter L, Lindgren
A, Conway AE, Clark AT, Goldman SA, Plath K, Wiedau-Pazos M, Kornblum
HI, Lowry WE: Directed differentiation of human-induced pluripotent
stem cells generates active motor neurons. Stem Cells 2009, 27:806–811.
45. Sareen D, O’Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M,
Bell S, Carmona S, Ornelas L, Sahabian A, Gendron T, Petrucelli L, Baughn M,
Ravits J, Harms MB, Rigo F, Bennett CF, Otis TS, Svendsen CN, Baloh RH:
Targeting RNA foci in iPSC-derived motor neurons from ALS patients
with a C9ORF72 repeat expansion. Sci Transl Med 2013, 5:208ra149.
46. Wada T, Honda M, Minami I, Tooi N, Amagai Y, Nakatsuji N, Aiba K: Highly
efficient differentiation and enrichment of spinal motor neurons derived
from human and monkey embryonic stem cells. PLoS One 2009, 4:e6722.
Faravelli et al. Stem Cell Research & Therapy Page 13 of 132014, 5:87
http://stemcellres.com/content/5/4/8747. Zeng H, Guo M, Martins-Taylor K, Wang X, Zhang Z, Park JW, Zhan S,
Kronenberg MS, Lichtler A, Liu HX, Chen FP, Yue L, Li XJ, Xu RH:
Specification of region-specific neurons including forebrain
glutamatergic neurons from human induced pluripotent stem cells.
PLoS One 2010, 5:e11853.
48. Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA: In vitro
differentiation of transplantable neural precursors from human
embryonic stem cells. Nat Biotechnol 2001, 19:1129–1133.
49. Lee H, Shamy GA, Elkabetz Y, Schofield CM, Harrsion NL, Panagiotakos G,
Socci ND, Tabar V, Studer L: Directed differentiation and transplantation
of human embryonic stem cell-derived motoneurons. Stem Cells 2007,
25:1931–1939.
50. Erceg S, Lainez S, Ronaghi M, Stojkovic P, Perez-Arago MA, Moreno-Manzano V,
Moreno-Palanques R, Planells-Cases R, Stojkovic M: Differentiation of human
embryonic stem cells to regional specific neural precursors in chemically
defined medium conditions. PLoS One 2008, 3:e2122.
51. Rungsiwiwut R, Manolertthewan C, Numchaisrika P, Ahnonkitpanit V,
Virutamasen P, Techakumphu M, Pruksananonda K: The ROCK inhibitor
Y-26732 enhances the survival and proliferation of human embryonic
stem cell-derived neural progenitor cells upon dissociation. Cells Tissues
Organs 2013, 198:127–138.
52. López-González R, Camacho-Arroyo I, Velasco I: Progesterone and
17beta-estradiol increase differentiation of mouse embryonic stem cells
to motor neurons. IUBMB Life 2011, 63:930–939.
53. Xue H, Wu S, Papadeas ST, Spusta S, Swistowska AM, MacArthur CC,
Mattson MP, Maragakis NJ, Capecchi MR, Rao MS, Zeng X, Liu Y: A targeted
neuroglial reporter line generated by homologous recombination in
human embryonic stem cells. Stem Cells 2009, 27:1836–1846.
54. Parker GC, Li X, Anguelov RA, Toth G, Cristescu A, Acsadi G: Survival motor
neuron protein regulates apoptosis in an in vitro model of spinal
muscular atrophy. Neurotox Res 2008, 13:39–48.
55. Marchetto MC, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH: Non-cell-
autonomous effect of human SOD1 G37R astrocytes on motor neurons
derived from human embryonic stem cells. Cell Stem Cell 2008, 3:649–657.
56. Han SS, Williams LA, Eggan KC: Constructing and deconstructing stem cell
models of neurological disease. Neuron 2011, 70:626–644.
57. Jung YW, Hysolli E, Kim KY, Tanaka Y, Park IH: Human induced pluripotent
stem cells and neurodegenerative disease: prospects for novel therapies.
Curr Opin Neurol 2012, 25:125–130.
58. Badger JL, Cordero-Llana O, Hartfield EM, Wade-Martins R: Parkinson’s
disease in a dish - using stem cells as a molecular tool.
Neuropharmacology 2014, 76:88–96.
59. Hermann A, Storch A: Induced neural stem cells (iNSCs) in
neurodegenerative diseases. J Neural Transm 2013, 120:S19–S25.
60. Qu Q, Li D, Louis KR, Li X, Yang H, Sun Q, Crandall SR, Tsang S, Zhou J, Cox
CL, Cheng J, Wang F: High-efficiency motor neuron differentiation from
human pluripotent stem cells and the function of Islet-1. Nat Commun
2014, 5:3449.
Cite this article as: Faravelli et al.: Motor neuron derivation from human
embryonic and induced pluripotent stem cells: experimental approaches
and clinical perspectives. Stem Cell Research & Therapy
10.1186/scrt476
2014, 5:87
